PBAC's latest decision on Brentuximab vedotin: Recommended with restriction (2025). Considered for First-line treatment of adult patients with previously untreated CD30+ advanced (stage III or IV) Hodgkin lymphoma in combination with doxorubicin, vinblastine and dacarbazine (A+AVD).
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
10
first 2014
Submissions
10
2014 → 2025
Eligible population
Adult patients with previously untreated CD30+ advanced (stage III or IV) Hodgkin lymphoma, treated with brentuximab vedotin in combination with doxorubicin, vinblastine and dacarbazine (A+AVD) for 6 × 28-day cycles.
Therapy area
Oncology
Line of therapy
First-line
Evidence base
RCT
Primary endpoint
PFS
Key trials
ECHELON-1, RATHL
Comparator
PET-adapted ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine)
Economic model
CUA
ICER note
ICER value not stated in the public text; the document indicates the economic model was revised to a Markov structure but the numeric ICER is not published.
ICER (historical)
$25k/QALY–$35k/QALY across 4 submissions (2014–2021) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
Submission history
Mar 2014: Recommended with restriction · Authority Required — ICER $75k/QALY